ea0098b28 | Basic Science | NANETS2023
Kaemmer Courtney
, Umesalma Shaikamjad
, Maharjan Chandra
, Kohlmeyer Jordan
, Lingo Joshua
, Wilkerson Emily
, Sheehy Ryan
, Leidinger Mariah
, Meyerholz David
, Bell Sarah
, Zamba Gideon
, Breheny Patrick
, Lattime Edmund
, Chandrasekharan Chandrikha
, Bellizzi Andrew
, Herring Laura
, Graves Lee
, Darbro Benjamin
, Yuan Ziqiang
, Libutti Steven
, Quelle Dawn
Background: New effective therapies are needed to improve the survival of patients with metastatic pancreatic NETs (pNETs). RABL6A is a novel oncogenic driver of pNET pathogenesis. Kinome and phosphoproteome analyses of proliferating (RABL6A-positive) pNET cells, vs arrested (RABL6A-knockdown) controls, demonstrated that cyclin-dependent kinase 4 and 6 (CDK4/6) and MEK kinases are actionable drug targets in growing pNET cells. In agreement, published studies of patient pNETs b...